SCHEMBL6773329

SCHEMBL6773329

O=C(NCc1ccc(F)cc1)C1(CCCCN2CCN(c3ccc4cccc(Cl)c4n3)CC2)c2ccccc2-c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.41
DRD3 P35462 11/20 0.40
DRD2 P14416 10/20 0.40
HTR1A P08908 6/20 0.40
DRD4 P21917 6/20 0.40
ADRA1A P35348 4/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1B P35368 2/20 0.40
HTR2A P28223 3/20 0.39
HTR7 P34969 3/20 0.39
HTR2C P28335 2/20 0.39
TP53 P04637 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
DRD1 P21728 2/20 0.37
CHRM2 P08172 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37
TBXA2R P21731 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7597290 0.89 HTR3A (0.39) HTR3ADRD3DRD2HTR1ADRD4
SCHEMBL6770133 0.89 HTR1A (0.49) HTR3ADRD3DRD2HTR1ADRD4
SCHEMBL6766415 0.88 HTR1A (0.51) HTR3ADRD3DRD2HTR1AHTR2A
SCHEMBL6771159 0.88 MTTP (0.49) DRD3ADRA1ADRD1CHRM2ADRA2A
SCHEMBL6793499 0.85 HTR1A (0.51) DRD3DRD2HTR1ADRD4HTR2A
SCHEMBL6795245 0.83 HTR1A (0.53) DRD3DRD2HTR1ADRD4ADRA1A
SCHEMBL6769621 0.82 HTR1A (0.53) HTR3ADRD3DRD2HTR1AHTR2A
SCHEMBL6771603 0.81 HTR1A (0.45) DRD3DRD2HTR1ADRD4ADRA1A
SCHEMBL6766578 0.80 HTR1A (0.51) HTR3ADRD3DRD2HTR1AHTR2A
SCHEMBL6776794 0.80 DRD3 (0.47) HTR3ADRD3DRD2HTR1ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A HTR3A 2835/4885DRD3 2928/4885DRD2 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.